Construction and validation of a prognostic prediction model based on albumin-bilirubin grade after resection of hepatocellular carcinoma
World Journal of Gastrointestinal Surgery · 2026-11-27 · 18 (11)
DOI: 10.4240/wjgs.122279 ↗Abstract
BACKGROUND Hepatocellular carcinoma (HCC) is one of the world's major health problems and high recurrence after curative resection limits long-term survival. Existing prognostic tools, such as Child-Pugh score, are limited by subjective aspects. Albumin-bilirubin (ALBI) grade (objective lab parameters) is shown to have an advantage in assessing liver function and prognosis. Given the limitations of existing prognostic tools and the proven prognostic value of ALBI grade in HCC, there is a need to develop an integrated, objective prediction model for postoperative recurrence risk stratification. AIM To construct and validate a prognostic prediction model based on ALBI grade after HCC resection. METHODS We looked back at clinical data from 596 patients with HCC who had a radical hepatectomy from 2021 to 2023. Using Kaplan-Meier analysis and Cox regression, we identified independent predictors of recurrence-free survival (RFS). We then built a nomogram that combines these predictors to estimate 1- and 2-year RFS. RESULTS In the ALBI 2/3 group, the median RFS was 20.0 months. While the median RFS in the ALBI level 1 group was not reached at the end of the study, the differences between the two groups were statistically significant (P < 0.001). Multifactor Cox regression analysis showed that ALBI score, age, tumor size, tumor number, and alpha-fetoprotein levels were independent predictors of the effect on RFS (P < 0.05). We built nomogram with a consistency index (C-index) of 0.647 in the training set and 0.643 in the validation set. From the results of the time dependency analysis, area under the curve was 0.638-0.676 in the 1- and 2-year RFS predictions. CONCLUSION ALBI grade independently predicts HCC postoperative recurrence. Our integrated nomogram combining ALBI and clinical factors enables personalized recurrence risk stratification to guide individualized postoperative management.
EUVIMED